NO20083031L - Tiadiazolderivater som anti-diabetiske agenter - Google Patents

Tiadiazolderivater som anti-diabetiske agenter

Info

Publication number: NO20083031L
Authority: NO; Norway
Prior art keywords: compounds; inhibitors; prevention; formula; treatment
Prior art date: 2005-12-08

Application number

NO20083031A

Other languages

English (en)

Norwegian (no)

Inventor

Gary Mark Coppola

Thalaththani Ralalage Vedananda

James Richard Wareing

Travis Mathew Stams

Sidney Wolf Topiol

Gregory Raymond Bebernitz

David Barnes

Katsumasa Nakajima

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-08

Filing date

2008-07-04

Publication date

2008-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37950917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083031(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-07-04 Application filed by Novartis Ag filed Critical Novartis Ag

2008-08-28 Publication of NO20083031L publication Critical patent/NO20083031L/no

Links

239000003472 antidiabetic agent Substances 0.000 title 1
229940125708 antidiabetic agent Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 3
108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 3
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 3
206010022489 Insulin Resistance Diseases 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
230000002265 prevention Effects 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
201000009030 Carcinoma Diseases 0.000 abstract 1
208000035473 Communicable disease Diseases 0.000 abstract 1
208000032928 Dyslipidaemia Diseases 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
208000002705 Glucose Intolerance Diseases 0.000 abstract 1
206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
206010033645 Pancreatitis Diseases 0.000 abstract 1
102000014400 SH2 domains Human genes 0.000 abstract 1
108050003452 SH2 domains Proteins 0.000 abstract 1
210000001789 adipocyte Anatomy 0.000 abstract 1
210000004204 blood vessel Anatomy 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
210000000987 immune system Anatomy 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
208000023589 ischemic disease Diseases 0.000 abstract 1
206010024627 liposarcoma Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
230000000626 neurodegenerative effect Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20083031A 2005-12-08 2008-07-04 Tiadiazolderivater som anti-diabetiske agenter NO20083031L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US74857305P	2005-12-08	2005-12-08
PCT/US2006/046545 WO2007067615A2 (en)	2005-12-08	2006-12-06	Thiadiazole derivatives as antidiabetic agents

Publications (1)

Publication Number	Publication Date
NO20083031L true NO20083031L (no)	2008-08-28

Family

ID=37950917

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20083031A NO20083031L (no)	2005-12-08	2008-07-04	Tiadiazolderivater som anti-diabetiske agenter

Country Status (26)

Country	Link
US (1)	US7700633B2 (de)
EP (1)	EP1963292B1 (de)
JP (1)	JP2009519248A (de)
KR (1)	KR20080074969A (de)
CN (1)	CN101326173A (de)
AR (1)	AR056838A1 (de)
AT (1)	ATE546440T1 (de)
AU (1)	AU2006321905B2 (de)
BR (1)	BRPI0619600A2 (de)
CA (1)	CA2629857A1 (de)
CR (1)	CR10049A (de)
EC (1)	ECSP088506A (de)
ES (1)	ES2381280T3 (de)
IL (1)	IL191549A0 (de)
MA (1)	MA30202B1 (de)
NO (1)	NO20083031L (de)
NZ (1)	NZ568243A (de)
PE (2)	PE20071031A1 (de)
PL (1)	PL1963292T3 (de)
PT (1)	PT1963292E (de)
RU (1)	RU2008127254A (de)
TN (1)	TNSN08249A1 (de)
TW (1)	TW200732315A (de)
UA (1)	UA94724C2 (de)
WO (1)	WO2007067615A2 (de)
ZA (1)	ZA200804074B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2630448A1 (en) *	2005-12-08	2007-06-14	Novartis Ag	1,1,3-trioxo-1,2,5-thiadiazolidines and their use as ptp-ases inhibitors
UA94921C2 (en)	2005-12-08	2011-06-25	Новартис Аг	1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
CA2629819A1 (en) *	2005-12-08	2007-06-14	Novartis Ag	1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
WO2008067527A1 (en) *	2006-12-01	2008-06-05	Novartis Ag	Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders
AR066820A1 (es) *	2007-06-04	2009-09-16	Novartis Ag	Compuestos de tiadiazolidin-3 ona
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5809157B2 (ja)	2010-10-08	2015-11-10	持田製薬株式会社	環状アミド誘導体
JPWO2012147516A1 (ja)	2011-04-28	2014-07-28	持田製薬株式会社	環状アミド誘導体
CN110536685A (zh)	2016-12-23	2019-12-03	昆士兰大学	Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病
BR112020026086A2 (pt) *	2018-06-21	2021-03-23	Calico Life Sciences Llc	inibidores da proteína tirosina fosfatase e métodos de uso destes
BR112021012311A2 (pt)	2018-12-21	2021-09-08	Crystal Pharma, S.A.U.	Uso de um composto intermediário, processo para preparar voxelotor e composto intermediário
IL286373B2 (en) *	2019-03-14	2026-03-01	Calico Life Sciences Llc	Protein tyrosine phosphate inhibitor compounds and uses thereof
GB201915094D0 (en) *	2019-10-18	2019-12-04	Balticgruppen Bio Ab	New formulations
US11691954B2 (en)	2019-10-18	2023-07-04	Betagenon Ab	Formulations
EP4073242A4 (de)	2019-12-12	2024-01-03	Kumquat Biosciences Inc.	Zusammensetzungen und verfahren zur potenzierung der immunaktivität
EP4077319A1 (de) *	2019-12-20	2022-10-26	Calico Life Sciences LLC	Protein-tyrosin-phosphatase-degradierer und verfahren zur verwendung davon
WO2022192598A1 (en) *	2021-03-11	2022-09-15	Kumquat Biosciences Inc.	Heterocycles and uses thereof
EP4359409A1 (de) *	2021-06-21	2024-05-01	Calico Life Sciences LLC	Degrader-verbindungen und verwendungen davon
WO2023086498A1 (en) *	2021-11-11	2023-05-19	Calico Life Sciences Llc	Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2023150150A1 (en) *	2022-02-02	2023-08-10	Nerio Therapeutics, Inc.	Protein tyrosine phosphatase inhibitors and uses thereof
WO2023150535A1 (en) *	2022-02-02	2023-08-10	Nerio Therapeutics, Inc.	Protein tyrosine phosphatase inhibitors and uses thereof
PE20250780A1 (es) *	2022-02-02	2025-03-14	Nerio Therapeutics Inc	Inhibidores de proteina tirosina fosfatasa y usos de estos
CN119790052A (zh) *	2022-09-13	2025-04-08	金橘生物科技公司	苯并稠合的n-杂环及其用途
WO2024067802A1 (zh) *	2022-09-30	2024-04-04	深圳众格生物科技有限公司	蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
WO2024141015A1 (en) *	2022-12-30	2024-07-04	Insilico Medicine Ip Limited	Protein tyrosine phosphatase inhibitors and uses thereof
CN118852335A (zh) *	2023-04-28	2024-10-29	中科中山药物创新研究院	噻二唑烷酮衍生物及其制备方法和应用
CN116496248B (zh) *	2023-05-06	2025-09-02	江苏艾科姆检测有限公司	一种溴氰虫酰胺杂质的合成方法
PE20252789A1 (es)	2023-05-24	2025-12-22	Kumquat Biosciences Inc	Compuestos heterociclicos y usos de estos
AU2024288616A1 (en) *	2023-07-11	2026-02-12	Shenzhen Zhongge Biological Technology Co., Ltd.	Protein tyrosine phosphatase inhibitor, composition comprising same, and medical use thereof
CN120004876B (zh) *	2023-11-16	2026-02-06	英矽智能科技(上海)有限公司	蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) *	2023-12-04	2024-02-06	英矽智能科技(上海)有限公司	蛋白酪氨酸磷酸酶抑制剂及其应用
WO2025242216A1 (zh) *	2024-05-24	2025-11-27	杭州百新生物医药科技有限公司	吲哚啉类化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100868587B1 (ko) *	2002-04-03	2008-11-12	노파르티스 아게	Ｐｔｐａｓｅ 1ｂ 억제제로서의 5-치환된1,1-디옥소-1,2,5-티아졸리딘-3-온 유도체
GB0225986D0 (en) *	2002-11-07	2002-12-11	Astrazeneca Ab	Chemical compounds
GB0227813D0 (en) *	2002-11-29	2003-01-08	Astrazeneca Ab	Chemical compounds
EP1594497B1 (de) *	2002-12-30	2009-05-27	Vertex Pharmaceuticals Incorporated	Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen
US7141596B2 (en) *	2003-10-08	2006-11-28	Incyte Corporation	Inhibitors of proteins that bind phosphorylated molecules
CA2630448A1 (en) *	2005-12-08	2007-06-14	Novartis Ag	1,1,3-trioxo-1,2,5-thiadiazolidines and their use as ptp-ases inhibitors
CA2629819A1 (en) *	2005-12-08	2007-06-14	Novartis Ag	1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
CA2647472A1 (en) *	2006-03-31	2007-10-11	Novartis Ag	Organic compounds

2006
- 2006-06-12 UA UAA200807751A patent/UA94724C2/ru unknown
- 2006-12-06 WO PCT/US2006/046545 patent/WO2007067615A2/en not_active Ceased
- 2006-12-06 JP JP2008544467A patent/JP2009519248A/ja active Pending
- 2006-12-06 BR BRPI0619600-4A patent/BRPI0619600A2/pt not_active IP Right Cessation
- 2006-12-06 AT AT06839094T patent/ATE546440T1/de active
- 2006-12-06 CA CA002629857A patent/CA2629857A1/en not_active Abandoned
- 2006-12-06 PL PL06839094T patent/PL1963292T3/pl unknown
- 2006-12-06 AR ARP060105392A patent/AR056838A1/es not_active Application Discontinuation
- 2006-12-06 PT PT06839094T patent/PT1963292E/pt unknown
- 2006-12-06 AU AU2006321905A patent/AU2006321905B2/en not_active Ceased
- 2006-12-06 CN CNA2006800461637A patent/CN101326173A/zh active Pending
- 2006-12-06 ES ES06839094T patent/ES2381280T3/es active Active
- 2006-12-06 PE PE2006001571A patent/PE20071031A1/es not_active Application Discontinuation
- 2006-12-06 PE PE2010000531A patent/PE20100733A1/es not_active Application Discontinuation
- 2006-12-06 EP EP06839094A patent/EP1963292B1/de active Active
- 2006-12-06 NZ NZ568243A patent/NZ568243A/en not_active IP Right Cessation
- 2006-12-06 KR KR1020087013716A patent/KR20080074969A/ko not_active Ceased
- 2006-12-06 US US12/096,439 patent/US7700633B2/en not_active Expired - Fee Related
- 2006-12-06 RU RU2008127254/04A patent/RU2008127254A/ru not_active Application Discontinuation
- 2006-12-07 TW TW095145713A patent/TW200732315A/zh unknown
2008
- 2008-05-13 ZA ZA200804074A patent/ZA200804074B/xx unknown
- 2008-05-19 IL IL191549A patent/IL191549A0/en unknown
- 2008-06-02 MA MA30987A patent/MA30202B1/fr unknown
- 2008-06-05 CR CR10049A patent/CR10049A/es not_active Application Discontinuation
- 2008-06-06 EC EC2008008506A patent/ECSP088506A/es unknown
- 2008-06-06 TN TNP2008000249A patent/TNSN08249A1/en unknown
- 2008-07-04 NO NO20083031A patent/NO20083031L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PE20071031A1 (es)	2007-11-15
ECSP088506A (es)	2008-07-30
EP1963292A2 (de)	2008-09-03
TW200732315A (en)	2007-09-01
US7700633B2 (en)	2010-04-20
ZA200804074B (en)	2009-03-25
PE20100733A1 (es)	2010-10-29
NZ568243A (en)	2011-07-29
PT1963292E (pt)	2012-05-10
ATE546440T1 (de)	2012-03-15
JP2009519248A (ja)	2009-05-14
ES2381280T3 (es)	2012-05-24
EP1963292B1 (de)	2012-02-22
CR10049A (es)	2008-08-25
US20080262050A1 (en)	2008-10-23
PL1963292T3 (pl)	2012-07-31
KR20080074969A (ko)	2008-08-13
WO2007067615A2 (en)	2007-06-14
IL191549A0 (en)	2008-12-29
BRPI0619600A2 (pt)	2011-10-11
WO2007067615A3 (en)	2007-11-15
MA30202B1 (fr)	2009-02-02
TNSN08249A1 (en)	2009-10-30
AU2006321905A1 (en)	2007-06-14
AU2006321905B2 (en)	2011-08-11
CA2629857A1 (en)	2007-06-14
RU2008127254A (ru)	2010-01-20
UA94724C2 (en)	2011-06-10
AR056838A1 (es)	2007-10-24
CN101326173A (zh)	2008-12-17

Legal Events

Date	Code	Title	Description
2013-07-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20083031L (no)	2008-08-28	Tiadiazolderivater som anti-diabetiske agenter
NO20083030L (no)	2008-08-28	1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer
WO2007115058A3 (en)	2008-03-20	Thiadiazolidinone inhibitors of ptpase
TNSN08247A1 (en)	2009-10-30	1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
NO20044745L (no)	2004-12-14	5-substituerte 1,1-diokso-1,2,5-tiazolidin-3-on-derivater som PTPASE 1B inhibitorer
Cameron et al.	2016	Discovery and preclinical characterization of 6-chloro-5-[4-(1-hydroxycyclobutyl) phenyl]-1 H-indole-3-carboxylic acid (PF-06409577), a direct activator of adenosine monophosphate-activated protein kinase (AMPK), for the potential treatment of diabetic nephropathy
AR066820A1 (es)	2009-09-16	Compuestos de tiadiazolidin-3 ona
Liu et al.	2019	p53 modifications: exquisite decorations of the powerful guardian
Pyner et al.	2017	Inhibition of human and rat sucrase and maltase activities to assess antiglycemic potential: Optimization of the assay using acarbose and polyphenols
WO2007070434A3 (en)	2008-03-06	Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
EP1921917A4 (de)	2010-08-04	Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
EP1796669A4 (de)	2009-08-19	Aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
EP1819674A4 (de)	2009-04-15	Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
NO20070506L (no)	2007-02-14	Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer.
WO2007149451A3 (en)	2008-02-21	Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
BRPI0606704A (pt)	2008-03-11	derivados de piridinila e pirimidinila substituìdos como moduladores do metabolismo e o tratamento de distúrbios relacionados ao mesmo
EA201270215A1 (ru)	2012-11-30	Apaf-1 ингибиторные соединения
WO2010036613A8 (en)	2010-11-18	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
NO20061197L (no)	2006-05-11	Proteasominhibitorer og fremgangsmater for anvendelse av samme
NO20076039L (no)	2008-01-24	TRPV1-agonistforbindelser og fremgangsmater for fremstilling og anvendelse av disse
NO20054769L (no)	2006-01-03	Substituerte fenylalkansyrer
WO2008054698A3 (en)	2008-06-19	Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008046082A3 (en)	2008-06-19	Use of heterocyclic compounds as therapeutic agents
BRPI0508144A (pt)	2007-07-24	derivados de oligossacarìdeos sulfatados composto da fórmula geral; composição farmacêutica ou veterinária seu uso; método para a prevenção ou tratamento pelo uso da mesma
Rotili et al.	2010	Identification of tri‐and tetracyclic pyrimidinediones as sirtuin inhibitors